<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment and prognosis of pulmonary alveolar proteinosis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment and prognosis of pulmonary alveolar proteinosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment and prognosis of pulmonary alveolar proteinosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward D Chan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 24, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pulmonary alveolar proteinosis (PAP), also known as pulmonary alveolar phospholipoproteinosis, is a diffuse lung disease characterized by the accumulation of amorphous, periodic acid-Schiff (PAS)-positive lipoproteinaceous material in the distal air spaces [<a href="#rid1">1-4</a>].</p><p>The most common symptoms are dyspnea and cough. Radiographic imaging typically reveals bilateral symmetric alveolar opacities located centrally in mid and lower lung zones, often in a "bat wing" distribution. Five forms of PAP are recognized  (<a class="graphic graphic_table graphicRef77313" href="/z/d/graphic/77313.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Disorders of surfactant production or metabolism due to genetic variants in surfactant and other proteins (also called congenital PAP)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disorders of granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling due to GM-CSF antibodies (also called primary PAP or autoimmune PAP in those with anti-GM-CSF antibodies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recessive genetic variants of GM-CSF receptor subunits</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying disorders that secondarily affect alveolar macrophage function, such as certain hematologic/immunologic/metabolic diseases, inhalational exposures, and infections (also called secondary PAP)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unclassified</p><p></p><p>The treatment and prognosis of PAP will be reviewed here. General approaches to adult and pediatric interstitial lung disease and the clinical manifestations and diagnosis of pulmonary alveolar proteinosis in adults are described separately. (See  <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a> and  <a class="medical medical_review" href="/z/d/html/6374.html" rel="external">"Approach to the infant and child with diffuse lung disease (interstitial lung disease)"</a> and  <a class="medical medical_review" href="/z/d/html/4373.html" rel="external">"Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults"</a>.)</p><p class="headingAnchor" id="H3029197329"><span class="h1">ASSESSMENT OF DISEASE SEVERITY</span><span class="headingEndMark"> — </span>In order to determine the appropriate treatment, severity of PAP is assessed using a combination of symptoms, serum level of lactic dehydrogenase (LDH), titer of serum antibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF) in autoimmune PAP, pulmonary function tests, and extent of opacities on high resolution computed tomography (HRCT) imaging [<a href="#rid5">5,6</a>]. Pulmonary function tests, including lung volumes, diffusing capacity, and six-minute walk with oxygen saturation determination, are used to assess the degree of impairment and to provide a baseline for long-term monitoring. (See  <a class="medical medical_review" href="/z/d/html/4373.html" rel="external">"Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults", section on 'Pulmonary function tests'</a>.)</p><p>The interpretation of GM-CSF antibody titers in serum and BAL before and during treatment requires further investigation [<a href="#rid7">7-9</a>]. In one study of 13 patients, initial BAL fluid levels of GM-CSF antibodies correlated better with the severity of PAP than serum titers [<a href="#rid10">10</a>]. In a separate study that administered subcutaneous GM-CSF over 12 or more weeks, serial GM-CSF antibody titers declined in patients who demonstrated a clinical response, but did not decline in nonresponders [<a href="#rid7">7</a>]. In contrast, serum GM-CSF antibody titers increased in patients receiving nebulized GM-CSF (but not placebo), despite clinical improvement [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H5"><span class="h1">TREATMENT OF AUTOIMMUNE PAP</span></p><p class="headingAnchor" id="H6"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The choice of treatment options for autoimmune PAP depends upon the severity of disease. This approach is based on observations that show a high rate of spontaneous remission among those with mild disease. In the largest series to study the natural history of autoimmune PAP, asymptomatic patients were most likely to have a stable to improving course with only 8 percent worsening during follow up [<a href="#rid5">5</a>]. Among symptomatic patients, the proportions with stable, improved, and worsening disease were about 45, 30, and 25 percent, respectively. Patients with longer disease duration were more likely to have progressive disease.</p><p>In order to obtain the best risk benefit balance when choosing therapy, we divide patients into the following categories:</p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic or mild symptoms (eg, dyspnea with moderate or greater exertion) with little or no physiologic impairment (eg, normal to mildly reduced diffusing capacity for carbon monoxide [DLCO], normal pulse oxygen saturation [SpO<sub>2</sub>] at rest with or without a mild decrease on exertion)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate-to-severe symptoms (eg, dyspnea with minimal exertion or at rest) and physiologic abnormalities (eg, requiring supplemental oxygen at rest)</p><p></p><p>During the course of treatment or observation, symptoms (eg, dyspnea, exercise tolerance), spirometry, diffusing capacity, ambulatory oximetry, and chest computed tomography (CT) scan are monitored. </p><p class="headingAnchor" id="H1844199350"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Since PAP causes dysfunction of lung macrophages, all patients with PAP should be counseled to obtain annual vaccinations against influenza, coronavirus disease 2019 (COVID-19), as well as age-appropriate vaccination against pneumococcal pneumonia and respiratory syncytial virus. (See  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a> and  <a class="medical medical_review" href="/z/d/html/142052.html" rel="external">"Respiratory syncytial virus infection in adults", section on 'Vaccination'</a>.)</p><p>Patients should also be advised not to smoke cigarettes as one study showed that among patients who undergo whole lung lavage, those who smoke cigarettes require twice as many sessions of whole lung lavage as nonsmokers [<a href="#rid11">11</a>].</p><p>Supplemental oxygen is provided according to current guidelines. (See  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H2260324217"><span class="h2">Asymptomatic or mild disease</span><span class="headingEndMark"> — </span>Patients who are asymptomatic with little or no physiologic impairment and those who have mild symptoms, normoxia at rest, and normoxia or mild hypoxemia on exertion do not require immediate treatment and can be observed with periodic reassessment of symptoms, oxygen saturation, pulmonary function tests, and/or chest imaging to identify any further deterioration. </p><p>Occasional spontaneous remission has been reported [<a href="#rid11">11,12</a>]. In a series of 120 patients with autoimmune PAP, 40 were managed without therapeutic intervention for PAP. Of these, 39 remained stable or achieved remission, while one died of a pulmonary infection [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1587336380"><span class="h2">Moderate-to-severe respiratory impairment</span><span class="headingEndMark"> — </span>Patients who have moderate to severe disease based on symptoms and physiologic testing may elect to proceed with whole lung lavage or a trial of experimental treatment (eg, subcutaneous or inhaled GM-CSF, or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>). A stepwise treatment approach has been suggested, beginning with whole lung lavage (WLL) for patients with moderate to severe symptoms [<a href="#rid13">13</a>]. If there is progression of disease or whole lung lavage is intolerable, inhaled GM-CSF can be given. Some patients may respond better to whole lung lavage followed by inhaled GM-CSF treatment, than to initial treatment with inhaled GM-CSF [<a href="#rid14">14</a>]. If there is inadequate response to whole lung lavage and GM-CSF or they are associated with unacceptable side effects, then rituximab may be tried. These options are described in the sections that follow.</p><p class="headingAnchor" id="H7"><span class="h3">Whole lung lavage</span><span class="headingEndMark"> — </span>For patients who have moderate-to-severe symptoms and hypoxemia, WLL under general anesthesia via a double-lumen endotracheal tube is the most widely accepted and effective form of treatment [<a href="#rid12">12,15-22</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – Specific indications for WLL have not been formally evaluated, but we use the combination of a definitive histologic diagnosis and one of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Resting PaO<sub>2</sub> &lt;65 mmHg (8.67 kPa, at sea level)</p><p class="bulletIndent2"><span class="glyph">•</span>Alveolar-arterial oxygen (A-aO<sub>2</sub>) difference ≥40 mmHg at rest</p><p class="bulletIndent2"><span class="glyph">•</span>Severe dyspnea and hypoxemia at rest or on exercise</p><p></p><p class="bulletIndent1">Contraindications include uncorrectable clotting disorders, anesthetic risks, and cardiopulmonary instability. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique</strong> – The technique of WLL is well described [<a href="#rid15">15-17,20,23</a>]. It is typically performed under general anesthesia [<a href="#rid24">24</a>]. A double-lumen endotracheal tube is inserted with the patient supine and the correct positioning of the tips in the trachea (lavage lung) and main bronchus (ventilated lung) confirmed by flexible bronchoscopy. The patient is placed in the lateral recumbent position with the lung to be lavaged nondependent. The dependent lung is ventilated and oxygenated using one lung ventilation. (See  <a class="medical medical_review" href="/z/d/html/14945.html" rel="external">"One lung ventilation: General principles"</a> and  <a class="medical medical_review" href="/z/d/html/14944.html" rel="external">"Lung isolation techniques"</a>.). </p><p></p><p class="bulletIndent1">A 15 to 20 L bag of normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> is hung from an intravenous (IV) pole, and the fluid is warmed to 37ºC by passing through a blood warmer. The lavage is performed by instilling 0.8 to 1.5 L aliquots of the warmed normal saline [<a href="#rid23">23</a>]. During each instillation, the patient is slanted to elevate the head slightly (lateral reverse Trendelenburg). After instillation of the lavage fluid, chest percussion is performed for four to five minutes [<a href="#rid25">25</a>], followed by positioning the patient slanted with the head down (lateral Trendelenburg position) for gravity drainage of the fluid through the endotracheal tube into a collection canister. A modified technique, in which the lavaged lung is manually bag-ventilated with 300 mL of air five times after instillation of 500 mL of saline was shown to significantly increase the removal of the lipoproteinaceous material [<a href="#rid26">26</a>]. A flexible bronchoscope is used, as needed, to inspect the lung and suction residual fluid. It has been suggested that repetitive manual hyperinflation (MH) and intermittent chest percussions may further enhance WLL efficacy [<a href="#rid27">27</a>]. </p><p></p><p class="bulletIndent1">Careful count of the volumes instilled and recovered is needed to avoid overdistension of the lung with unrecovered fluid; not more than 200 to 300 mL should accumulate in the lungs unrecovered. While practice varies, the total volume of lavage fluid approximates 15 L, spread over 10 to 15 lavages  (<a class="graphic graphic_picture graphicRef82575" href="/z/d/graphic/82575.html" rel="external">picture 1</a>). The initial lavage effluent appears thick and milky, while the final lavage appears clear [<a href="#rid20">20,28</a>]. </p><p></p><p class="bulletIndent1">For the majority of patients, unilateral lung lavage is performed on the first day followed by lavage of the opposite lung one to two weeks later [<a href="#rid23">23</a>]. However, bilateral sequential WLL has been performed in a single treatment session. Because one lung is ventilated while the other undergoes lavage, it seems logical to first perform lavage on the side that is worse while ventilating the less affected lung to minimize desaturation during the procedure. For patients with severely compromised gas exchange, extracorporeal membrane oxygenation has been used to support the patient during WLL [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1">Meticulous charting and monitoring of oxygenation, dynamic lung compliance, correct position of the double-lumen endotracheal tube, and recovery of the infused <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> are necessary to avoid and to quickly diagnose complications. </p><p></p><p class="bulletIndent1">After the procedure, an upright chest radiograph is obtained to exclude pneumothorax. As impairment of oxygenation can occur due to residual lavage fluid or incompletely treated PAP, continued intubation and mechanical ventilation in the intensive care unit may be required (typically &lt;24 hours) prior to extubation and discharge [<a href="#rid4">4,30</a>]. </p><p></p><p class="bulletIndent1">Complications of WLL include malpositioning of the endotracheal tube, <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> spillover into the opposite ventilated lung, intraprocedural hypoxemia, pneumothorax, and hydropneumothorax.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – After WLL, patients often feel dramatically better, with substantial improvement in exertional dyspnea and oxygenation despite only small changes in pulmonary function [<a href="#rid31">31</a>]. The subsequent clinical course is variable. Thirty to 50 percent of patients require only one lavage, while others require repeat lung lavages at intervals of 6 to 12 months [<a href="#rid12">12,17,18</a>]. Of note, cigarette smokers are more likely to require repeat WLL than nonsmokers [<a href="#rid11">11,18</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a series of 80 patients with autoimmune PAP who received WLL, 56 (70 percent) achieved a sustained remission with one lavage, while 24 (30 percent) required one or more additional treatments [<a href="#rid12">12</a>]. Of those who required additional treatments, 19 remained stable or improved and 5 developed refractory disease. Patients with an initial DLCO of 42 percent predicted or less were more likely to require additional WLL.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a separate series of 60 patients who underwent WLL, 40 achieved remission after one or more lavages and another 10 required repeated WLL [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Recombinant GM-CSF</span><span class="headingEndMark"> — </span>Experience with recombinant GM-CSF (molgramostim, <a class="drug drug_general" data-topicid="9878" href="/z/d/drug information/9878.html" rel="external">sargramostim</a>) by inhalation or subcutaneous injection is increasing, although it remains off-label for autoimmune PAP. Initial work suggests that the proportion of responders to GM-CSF is less than with WLL [<a href="#rid32">32-35</a>]. Given the investigational nature of GM-CSF therapy, we use WLL as primary therapy [<a href="#rid32">32,33,36-39</a>] and reserve recombinant GM-CSF for patients who cannot undergo or have failed WLL [<a href="#rid14">14,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/4373.html" rel="external">"Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults", section on 'Role of GM-CSF'</a>.)</p><p>Based on greater ease of administration and as good and possibly better response of nebulized compared with subcutaneous GM-CSF, the nebulized route can be tried first [<a href="#rid33">33,35</a>]. Sequential treatment with inhaled GM-CSF after initial WLL is a reasonable strategy that greatly reduced the need for repeat WLL over 30 months of follow-up (78 versus 11 percent) in one small placebo-controlled trial of patients with moderate to severe autoimmune PAP [<a href="#rid41">41</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled GM-CSF</strong> – Nebulized recombinant GM-CSF modestly improves lung function and may facilitate clearance of the GM-CSF-antibody complex from the lung [<a href="#rid35">35,42-46</a>]. For inhalational administration, recombinant GM-CSF is reconstituted in 2 mL of normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and administered via nebulizer. Accumulating data from randomized trials and observational studies suggest modest improvement in symptoms and respiratory physiology with inhaled GM-CSF therapy [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">In the largest randomized trial, 138 adults with substantial respiratory impairment due to autoimmune PAP (baseline AaO<sub>2</sub> gradient approximately 40 mmHg, DLCO approximately 50 percent of predicted and an average of three to four prior whole lung lavages per patient) were assigned to one of three groups, recombinant GM-CSF (molgramostim) 300 mcg per day continuously, recombinant GM-CSF 300 mcg per day during alternate weeks (“intermittent”), or placebo, via mesh nebulizer [<a href="#rid48">48</a>]. After 24 weeks, the AaO<sub>2</sub> difference improved (decreased) from baseline to week 24 by -12.8 mmHg in the continuous group versus -6.6 mmHg in the placebo group (treatment difference -6.2 mmHg; p=0.03), with no significant difference in the change of the AaO<sub>2</sub> gradient between placebo and "intermittent" groups. The group that received continuous GM-CSF also had significantly greater improvement in DLCO compared with placebo (12.0 versus 4.2 percent). The St. George’s Respiratory Questionnaire (SGRQ) score, a measure of overall health status in patients with respiratory disease, improved by -7.4 points in the continuous molgramostim group compared with placebo (minimal clinically important difference -4 points). The six-minute walk distance and time to first WLL were similar between groups, although the rate of WLL decreased over time in the continuous therapy group. Adverse events were similar between groups. Chest pain was more frequent in the continuous treatment group.</p><p></p><p class="bulletIndent1">In a prior randomized trial of patients with autoimmune PAP and mild-to-moderate respiratory impairment, patients (n = 64) received GM-CSF 125 mcg or placebo by nebulization twice daily on days 1 through 7 and none on days 8 through 14 with the two-week cycles repeated 12 times (24 week period) [<a href="#rid9">9</a>]. After 25 weeks, the A-aO<sub>2</sub> difference improved from baseline in the GM-CSF treatment group relative to the placebo group (difference -5.70 [95% CI -10.50 to -1.40]). Borderline improvements were noted in the modified Medical Research Council dyspnea scale, DLCO, and lung density on chest CT. There was no difference in the six-minute walk distance between the GM-CSF and placebo groups. While there was individual variability, serum GM-CSF antibodies increased in the GM-CSF group and decreased in the placebo group. The patients in this study had milder respiratory impairment compared with prior studies, which may explain the lack of clinical benefit.</p><p></p><p class="bulletIndent1">In a separate placebo-controlled trial, inhaled recombinant human GM-CSF was associated with decreased (improved) mean (±SD) alveolar-arterial oxygen gradient in the GM-CSF group (33 patients) than in the placebo group (30 patients; mean change from baseline, −4.50±9.03 versus 0.17±10.50 mm Hg; 95% CI of the difference -1.4 to -10.5 mm Hg) [<a href="#rid9">9</a>]. There was no significant difference in adverse events between the GM-CSF and placebo-treated patients (six and three events, respectively), and the serious events were felt likely unrelated to treatment.</p><p></p><p class="bulletIndent1">Small open-label studies support a beneficial effect with no reported adverse effects during 12- to 24-week trials [<a href="#rid35">35,49-51</a>]. In another study, GM-CSF inhalation was associated with a decrease in GM-CSF autoantibodies in the bronchoalveolar lavage fluid from improved patients, but not in the serum, suggesting that GM-CSF inhalation did not affect autoantibody production [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subcutaneous GM-CSF</strong> – The response rate to subcutaneous recombinant GM-CSF is slightly less than 50 percent. In an open label trial of 25 patients, recombinant human GM-CSF was given subcutaneously, starting at 250 mcg/day for one month, increasing to 5 mcg/kg/day for the second month, and 9 mcg/kg/day for the third month [<a href="#rid33">33</a>]. Responders were continued on this dose for 12 months; those with a suboptimal clinical response were given further dose escalations up to 18 mcg/kg/day. Overall, 48 percent experienced symptomatic and radiographic improvement. (See  <a class="medical medical_review" href="/z/d/html/8383.html" rel="external">"Introduction to recombinant hematopoietic growth factors"</a> and <a class="local">'Clinical trials'</a> below.)</p><p></p><p class="bulletIndent1">Declining serum GM-CSF antibody levels appear to correlate with a positive response to GM-CSF therapy [<a href="#rid7">7,33,39</a>]. Adverse effects are mild and include fever, fatigue, headache, and injection site complications [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">Many patients with autoimmune PAP do not manifest a normal hematologic response to parenteral GM-CSF; very high doses of the growth factor may be required to achieve a modest elevation in the white blood cell count [<a href="#rid34">34,49</a>]. </p><p></p><p class="headingAnchor" id="H344144024"><span class="h2">Refractory disease</span><span class="headingEndMark"> — </span>The optimal therapy for patients with progressive respiratory impairment despite WLL and therapy with GM-CSF is not known. Choosing among investigational therapy (eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, therapeutic plasma exchange), participation in a clinical trial, or lung transplantation will need to be made on a case-by-case basis. </p><p class="headingAnchor" id="H656891501"><span class="h3">Rituximab</span><span class="headingEndMark"> — </span>A few studies have investigated the role of the anti-CD20 monoclonal antibody, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid53">53-56</a>]. In an open-label, phase II study of 10 patients with autoimmune PAP, rituximab (1 g) was infused intravenously for two doses about two weeks apart [<a href="#rid55">55</a>]. Compared with pretreatment values, both the arterial oxygen tension (PaO<sub>2</sub>) and A-aO<sub>2</sub> difference significantly improved at three and six months after treatment. The mean HRCT score also improved following rituximab treatment. Interestingly, both the total anti-GM-CSF IgG level and the capacity to neutralize GM-CSF activity decreased in the bronchoalveolar lavage fluid six months after treatment but no difference in either was seen in the pre- and post-treatment sera. In contrast, a retrospective study of 13 patients failed to support rituximab as a second line therapy for patients with refractory autoimmune PAP. Rituximab was well tolerated, however, objective improvement was seen in only 4 of the 13 patients treated (30 percent) after 12 months of follow-up [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H3237503455"><span class="h3">Therapeutic plasma exchange</span><span class="headingEndMark"> — </span>A small number of reports describe therapeutic plasma exchange (TPE, plasmapheresis) in patients who have failed to improve with WLL [<a href="#rid7">7,8,58,59</a>]. One patient did not improve with TPE, another responded to low intensity TPE over two months, and a third responded to five consecutive days of TPE followed by <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. It is possible that a more intensive TPE regimen is needed to clear anti-GM-CSF antibodies [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H1173457620"><span class="h3">Clinical trials</span><span class="headingEndMark"> — </span>Patients with PAP may wish to participate in a clinical trial (eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, GM-CSF). Additional information is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=4356" target="_blank">https://clinicaltrials.gov</a>.</p><p class="headingAnchor" id="H2145302152"><span class="h3">Lung transplantation</span><span class="headingEndMark"> — </span>Lung transplantation has been performed in a small number of patients with autoimmune PAP, some of whom developed recurrent disease in the lung allograft [<a href="#rid60">60-63</a>]. Selection of potential lung transplant recipients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a>.)</p><p class="headingAnchor" id="H4107753269"><span class="h2">Future directions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gene-corrected pluripotent stem cells</strong> – Derivation of macrophages from gene-corrected pluripotent stem cells is a promising investigational method of reconstituting the defective macrophage population in patients with hereditary PAP [<a href="#rid64">64,65</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statins</strong> – Because alveolar macrophages from patients with autoimmune PAP have a markedly increased ratio of cholesterol to phospholipids, studies have explored the possibility that targeting cholesterol homeostasis might be a useful therapeutic approach for PAP [<a href="#rid66">66</a>]. Statin-induced lowering of intracellular cholesterol accumulation leads to improvements in surfactant uptake and clearance by alveolar macrophages. Several reports describe patients with autoimmune PAP in whom treatment with statins led to improvements in lung function, oxygenation and radiologic findings [<a href="#rid66">66,67</a>].</p><p></p><p class="headingAnchor" id="H3529427691"><span class="h2">Ineffective therapies</span><span class="headingEndMark"> — </span>There is no role for glucocorticoids or other immunosuppressive agents as primary therapy for autoimmune PAP; glucocorticoids may actually increase mortality [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H4046691396"><span class="h1">TREATMENT OF OTHER TYPES OF PAP</span><span class="headingEndMark"> — </span>The optimal treatment of secondary, hereditary, and congenital PAP has not been determined. As in autoimmune PAP, whole lung lavage (WLL) is often used for patients with moderate to severe symptoms and hypoxemia [<a href="#rid11">11</a>]. All patients are advised to obtain annual vaccinations against influenza and COVID-19, as well as age-appropriate vaccination against pneumococcal pneumonia and respiratory syncytial virus. Cigarette smokers should be advised to stop smoking.</p><p>Treatments that are more specific to the cause of PAP include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary PAP due to hematologic dyscrasias</strong> – For patients with hematologic malignancy or myelodysplasia, treatment of the underlying process may lead to improvement in PAP [<a href="#rid70">70,71</a>]. For patients with myelodysplastic syndrome in general, WLL has had mixed success [<a href="#rid70">70,72</a>]. </p><p></p><p class="bulletIndent1">Nonmyeloablative hematopoietic stem cell transplantation (HSCT) has been used to treat immunodeficiency due to familial myelodysplastic syndrome (genetic variants in GATA2), sometimes in combination with WLL [<a href="#rid70">70</a>]. (See <a class="local">'Whole lung lavage'</a> above and  <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes", section on 'Familial MDS/AML with mutated GATA2'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary PAP due to inhalational exposures</strong> – For patients with PAP following inhalational exposure, the most important intervention is to completely discontinue further exposures. Results with WLL have been mixed: one patient with dust exposure following an earthquake did respond [<a href="#rid73">73</a>]; one of two patients with PAP following indium tin oxide exposure experienced improvement with WLL [<a href="#rid74">74</a>]; and one patient with PAP following aluminium exposure did not respond [<a href="#rid75">75</a>]. Case reports have described successful WLL in some but not all patients with acute silicoproteinosis, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4321.html" rel="external">"Silicosis", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PAP due to GM-CSF receptor variants</strong> – HSCT may be a potential treatment for patients with abnormal GM-CSF signalling due to GM-CSF receptor variants. HSCT has reversed PAP in GM-CSF receptor-deficient mice and has been suggested (but not yet undertaken) in humans [<a href="#rid76">76</a>]. One patient with a <em>CSF2RB</em> (gene that encodes for beta-subunit of the receptor for GM-CSF) nonsense mutation who underwent bilateral lung transplantation developed recurrent PAP after nine months [<a href="#rid77">77</a>]. It was noted that the alveolar macrophage population in the lung allograft had been almost completely replaced by macrophages of recipient origin, suggesting that HSCT may be necessary to prevent the return of alveolar macrophages with aberrant GM-CSF receptors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital PAP</strong> – The management of congenital disorders of surfactant production, such as variants in the genes for surfactant proteins (SP)-B or C, proteins involved in the metabolism of surfactant (ATP-binding cassette, subfamily A (ABCA3), or NK2 homeobox-1 (NKX2.1) thyroid transcription factor-1 (TTF1), is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">"Genetic disorders of surfactant dysfunction", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1">Based on a few cases, patients with lysinuric protein intolerance and certain methionyl-tRNA synthetase (MARS) variants, which lead to impaired surfactant production, are managed with dietary modification, occasionally WLL, and rarely inhaled GM-CSF in refractory cases [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">"Genetic disorders of surfactant dysfunction", section on 'Related disorders'</a> and  <a class="medical medical_review" href="/z/d/html/6351.html" rel="external">"Pulmonary alveolar proteinosis in children", section on 'Congenital PAP'</a>.)</p><p></p><p class="headingAnchor" id="H3638885172"><span class="h1">INFECTIOUS COMPLICATIONS</span><span class="headingEndMark"> — </span>Patients with PAP have an increased risk of superinfection with opportunistic organisms such as Nocardia, actinomyces, mycobacteria, and various endemic or opportunistic fungi, due to impaired macrophage and neutrophil function [<a href="#rid5">5,78-85</a>].</p><p class="headingAnchor" id="H11"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The long-term prognosis of PAP has not been extensively described [<a href="#rid12">12,17,18,86</a>]. Up to 30 percent may achieve remission or remain stable without specific therapy, while 70 to 90 percent achieve remission or stability with one or more whole lung lavages(WLLs) [<a href="#rid11">11,12,18</a>]. The development of high-resolution computed tomography (HRCT) findings consistent with parenchymal fibrosis portends a poorer outcome [<a href="#rid87">87</a>].</p><p>The fact that some patients with autoimmune PAP have a self-limited course has led to the hypothesis that some cases of PAP result from an acquired clonal disorder of hematopoietic cells [<a href="#rid49">49</a>]. Remission may result from subsequent displacement of this abnormal clone from the hematopoietic pool.</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – The choice of treatment options for patients with pulmonary alveolar proteinosis (PAP) depends on the etiology of PAP and the severity of symptoms and gas exchange abnormalities. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who smoke should be advised to stop smoking.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients with PAP should be counseled to obtain annual vaccinations against influenza, COVID-19, and respiratory syncytial virus (if no contraindications) as well as age-appropriate vaccination against pneumococcal pneumonia. (See <a class="local">'Treatment of autoimmune PAP'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minimal or mild disease</strong> – For patients with minimal or no symptoms or physiologic impairment (eg, normal blood oxygen levels at rest, mild reduction in diffusing capacity for carbon monoxide [DLCO], or exercise-related hypoxemia), we prefer supportive care with supplemental oxygen, as needed, over more invasive therapy. These patients need periodic reassessment of symptoms, rest and walking oxygen saturation, pulmonary function tests, and chest imaging to identify deterioration that would require specific therapy, but many have a spontaneous remission. (See <a class="local">'Treatment of autoimmune PAP'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate or severe autoimmune PAP</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with moderate-to-severe dyspnea and hypoxemia due to autoimmune PAP, we recommend whole lung lavage (WLL) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The procedure is performed under general anesthesia via a double-lumen endotracheal tube. Generally, one lung is lavaged in the first procedure, followed by lavage of the opposite lung one to two weeks later. (See <a class="local">'Whole lung lavage'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recombinant granulocyte macrophage-colony stimulating factor (GM-CSF, <a class="drug drug_general" data-topicid="9878" href="/z/d/drug information/9878.html" rel="external">sargramostim</a>) administered by inhalation or subcutaneous injection is not approved for use in autoimmune PAP, but it may be an option for those who cannot undergo or have not responded to WLL. It may also be effective in reducing need for or frequency of recurrent WLL. (See <a class="local">'Recombinant GM-CSF'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glucocorticoids are not indicated for autoimmune PAP. (See <a class="local">'Ineffective therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional options for autoimmune PAP in those with refractory disease or who do not tolerate therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Therapies such as <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and therapeutic plasma exchange have been employed in individual patients who did not respond to or were intolerant of WLL and/or GM-CSF; further data are needed before routinely recommending these options. (See <a class="local">'Refractory disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who wish to participate in a clinical trial, additional information is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=4356" target="_blank">https://clinicaltrials.gov</a>. (See <a class="local">'Clinical trials'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lung transplantation is reserved for selected patients with severe, refractory PAP, although PAP sometimes recurs in the allograft. (See <a class="local">'Lung transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of secondary and hereditary PAP</strong> – Treatment options for patients with secondary and hereditary PAP are less clear and depend in part on the specific cause. (See <a class="local">'Treatment of other types of PAP'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most of these processes, WLL is performed in patients with moderate-to-severe symptoms and hypoxemia, based on the success in autoimmune PAP, although experience is limited. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additionally, certain types of secondary PAP may respond to specific therapy, such as treatment of an underlying hematologic malignancy, hematopoietic stem cell transplantation (HSCT) for familial myelodysplastic syndrome, and avoidance of occupational dust exposures.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The management of congenital disorders of surfactant production, which usually present in childhood, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">"Genetic disorders of surfactant dysfunction", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious complications of PAP</strong> – Patients with PAP have an increased risk of superinfection with opportunistic organisms such as Nocardia, mycobacteria, and various endemic or opportunistic fungi. (See <a class="local">'Infectious complications'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shah PL, Hansell D, Lawson PR, et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax 2000; 55:67.</a></li><li><a class="nounderline abstract_t">Kariman K, Kylstra JA, Spock A. Pulmonary alveolar proteinosis: prospective clinical experience in 23 patients for 15 years. Lung 1984; 162:223.</a></li><li><a class="nounderline abstract_t">Milleron BJ, Costabel U, Teschler H, et al. Bronchoalveolar lavage cell data in alveolar proteinosis. Am Rev Respir Dis 1991; 144:1330.</a></li><li><a class="nounderline abstract_t">Kumar A, Abdelmalak B, Inoue Y, Culver DA. Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. Lancet Respir Med 2018; 6:554.</a></li><li><a class="nounderline abstract_t">Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008; 177:752.</a></li><li><a class="nounderline abstract_t">Sui X, Du Q, Xu KF, et al. Quantitative assessment of Pulmonary Alveolar Proteinosis (PAP) with ultra-dose CT and correlation with Pulmonary Function Tests (PFTs). PLoS One 2017; 12:e0172958.</a></li><li><a class="nounderline abstract_t">Bonfield TL, Kavuru MS, Thomassen MJ. Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 2002; 105:342.</a></li><li><a class="nounderline abstract_t">Luisetti M, Rodi G, Perotti C, et al. Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J 2009; 33:1220.</a></li><li><a class="nounderline abstract_t">Tazawa R, Ueda T, Abe M, et al. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. N Engl J Med 2019; 381:923.</a></li><li><a class="nounderline abstract_t">Lin FC, Chang GD, Chern MS, et al. Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax 2006; 61:528.</a></li><li><a class="nounderline abstract_t">Suzuki T, Trapnell BC. Pulmonary Alveolar Proteinosis Syndrome. Clin Chest Med 2016; 37:431.</a></li><li><a class="nounderline abstract_t">Zhao YY, Huang H, Liu YZ, et al. Whole Lung Lavage Treatment of Chinese Patients with Autoimmune Pulmonary Alveolar Proteinosis: A Retrospective Long-term Follow-up Study. Chin Med J (Engl) 2015; 128:2714.</a></li><li><a class="nounderline abstract_t">Leth S, Bendstrup E, Vestergaard H, Hilberg O. Autoimmune pulmonary alveolar proteinosis: treatment options in year 2013. Respirology 2013; 18:82.</a></li><li><a class="nounderline abstract_t">Ohkouchi S, Akasaka K, Ichiwata T, et al. Sequential Granulocyte-Macrophage Colony-Stimulating Factor Inhalation after Whole-Lung Lavage for Pulmonary Alveolar Proteinosis. A Report of Five Intractable Cases. Ann Am Thorac Soc 2017; 14:1298.</a></li><li><a class="nounderline abstract_t">Claypool WD, Rogers RM, Matuschak GM. Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis). Chest 1984; 85:550.</a></li><li><a class="nounderline abstract_t">LARSON RK, GORDINIER R. PULMONARY ALVEOLAR PROTEINOSIS. REPORT OF SIX CASES, REVIEW OF THE LITERATURE, AND FORMULATION OF A NEW THEORY. Ann Intern Med 1965; 62:292.</a></li><li><a class="nounderline abstract_t">Beccaria M, Luisetti M, Rodi G, et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 2004; 23:526.</a></li><li><a class="nounderline abstract_t">Bonella F, Bauer PC, Griese M, et al. Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Respir Med 2011; 105:1908.</a></li><li><a class="nounderline abstract_t">Borie R, Danel C, Debray MP, et al. Pulmonary alveolar proteinosis. Eur Respir Rev 2011; 20:98.</a></li><li><a class="nounderline abstract_t">Michaud G, Reddy C, Ernst A. Whole-lung lavage for pulmonary alveolar proteinosis. Chest 2009; 136:1678.</a></li><li><a class="nounderline abstract_t">Gay P, Wallaert B, Nowak S, et al. Efficacy of Whole-Lung Lavage in Pulmonary Alveolar Proteinosis: A Multicenter International Study of GELF. Respiration 2017; 93:198.</a></li><li><a class="nounderline abstract_t">Kaenmuang P, Navasakulpong A. Efficacy of whole lung lavage in pulmonary alveolar proteinosis: a 20-year experience at a reference center in Thailand. J Thorac Dis 2021; 13:3539.</a></li><li><a class="nounderline abstract_t">Campo I, Luisetti M, Griese M, et al. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. Orphanet J Rare Dis 2016; 11:115.</a></li><li><a class="nounderline abstract_t">Tan Z, Tan KT, Poopalalingam R. Anesthetic Management for Whole Lung Lavage in Patients with Pulmonary Alveolar Proteinosis. A A Case Rep 2016; 6:234.</a></li><li><a class="nounderline abstract_t">Hammon WE, McCaffree DR, Cucchiara AJ. A comparison of manual to mechanical chest percussion for clearance of alveolar material in patients with pulmonary alveolar proteinosis (phospholipidosis). Chest 1993; 103:1409.</a></li><li><a class="nounderline abstract_t">Bonella F, Bauer PC, Griese M, et al. Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis. Eur Respir J 2012; 40:1468.</a></li><li><a class="nounderline abstract_t">Grutters LA, Smith EC, Casteleijn CW, et al. Increased Efficacy of Whole Lung Lavage Treatment in Alveolar Proteinosis Using a New Modified Lavage Technique. J Bronchology Interv Pulmonol 2021; 28:215.</a></li><li><a class="nounderline abstract_t">Nimmatoori DP, Bansal S, Singhania N, et al. Milky fluid from the lungs: pulmonary alveolar proteinosis. Intern Emerg Med 2021; 16:781.</a></li><li><a class="nounderline abstract_t">Vymazal T, Krecmerova M. Respiratory strategies and airway management in patients with pulmonary alveolar proteinosis: a review. Biomed Res Int 2015; 2015:639543.</a></li><li><a class="nounderline abstract_t">Hunter Guevara LR, Gillespie SM, Klompas AM, et al. Whole-lung lavage in a patient with pulmonary alveolar proteinosis. Ann Card Anaesth 2018; 21:215.</a></li><li><a class="nounderline abstract_t">Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002; 166:215.</a></li><li><a class="nounderline abstract_t">Kavuru MS, Sullivan EJ, Piccin R, et al. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161:1143.</a></li><li><a class="nounderline abstract_t">Venkateshiah SB, Yan TD, Bonfield TL, et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 2006; 130:227.</a></li><li><a class="nounderline abstract_t">Latzin P, Tredano M, Wüst Y, et al. Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Thorax 2005; 60:39.</a></li><li><a class="nounderline abstract_t">Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010; 181:1345.</a></li><li><a class="nounderline abstract_t">Seymour JF, Dunn AR, Vincent JM, et al. Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. N Engl J Med 1996; 335:1924.</a></li><li><a class="nounderline abstract_t">Barraclough RM, Gillies AJ. Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy. Thorax 2001; 56:664.</a></li><li><a class="nounderline abstract_t">de Vega MG, Sánchez-Palencia A, Ramírez A, et al. GM-CSF therapy in pulmonary alveolar proteinosis. Thorax 2002; 57:837.</a></li><li><a class="nounderline abstract_t">Seymour JF, Doyle IR, Nakata K, et al. Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax 2003; 58:252.</a></li><li><a class="nounderline abstract_t">Tanner LM, Kurko J, Tringham M, et al. Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance. JIMD Rep 2016.</a></li><li><a class="nounderline abstract_t">Campo I, Carey BC, Paracchini E, et al. Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients. Eur Respir J 2024; 63.</a></li><li><a class="nounderline abstract_t">Khan A, Agarwal R, Aggarwal AN. Effectiveness of granulocyte-macrophage colony-stimulating factor therapy in autoimmune pulmonary alveolar proteinosis: a meta-analysis of observational studies. Chest 2012; 141:1273.</a></li><li><a class="nounderline abstract_t">Tazawa R, Hamano E, Arai T, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2005; 171:1142.</a></li><li><a class="nounderline abstract_t">Wylam ME, Ten R, Prakash UB, et al. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006; 27:585.</a></li><li><a class="nounderline abstract_t">Robinson TE, Trapnell BC, Goris ML, et al. Quantitative analysis of longitudinal response to aerosolized granulocyte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis. Chest 2009; 135:842.</a></li><li><a class="nounderline abstract_t">Ohashi K, Sato A, Takada T, et al. Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis. Respir Med 2012; 106:284.</a></li><li><a class="nounderline abstract_t">Munsif M, Sweeney D, Leong TL, Stirling RG. Nebulised granulocyte-macrophage colony-stimulating factor (GM-CSF) in autoimmune pulmonary alveolar proteinosis: a systematic review and meta-analysis. Eur Respir Rev 2023; 32.</a></li><li><a class="nounderline abstract_t">Trapnell BC, Inoue Y, Bonella F, et al. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. N Engl J Med 2020; 383:1635.</a></li><li><a class="nounderline abstract_t">Seymour JF, Begley CG, Dirksen U, et al. Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis. Blood 1998; 92:2657.</a></li><li><a class="nounderline abstract_t">Papiris SA, Tsirigotis P, Kolilekas L, et al. Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose. Clin Drug Investig 2014; 34:553.</a></li><li><a class="nounderline abstract_t">Tian X, Yang Y, Chen L, et al. Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up. Orphanet J Rare Dis 2020; 15:174.</a></li><li><a class="nounderline abstract_t">Ohashi K, Sato A, Takada T, et al. Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis. Eur Respir J 2012; 39:777.</a></li><li><a class="nounderline abstract_t">Borie R, Debray MP, Laine C, et al. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J 2009; 33:1503.</a></li><li><a class="nounderline abstract_t">Amital A, Dux S, Shitrit D, et al. Therapeutic effectiveness of rituximab in a patient with unresponsive autoimmune pulmonary alveolar proteinosis. Thorax 2010; 65:1025.</a></li><li><a class="nounderline abstract_t">Kavuru MS, Malur A, Marshall I, et al. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J 2011; 38:1361.</a></li><li><a class="nounderline abstract_t">Malur A, Kavuru MS, Marshall I, et al. Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis. Respir Res 2012; 13:46.</a></li><li><a class="nounderline abstract_t">Soyez B, Borie R, Menard C, et al. Rituximab for auto-immune alveolar proteinosis, a real life cohort study. Respir Res 2018; 19:74.</a></li><li><a class="nounderline abstract_t">Kavuru MS, Bonfield TL, Thomassen MJ. Plasmapheresis, GM-CSF, and alveolar proteinosis. Am J Respir Crit Care Med 2003; 167:1036; author reply 1036.</a></li><li><a class="nounderline abstract_t">Garber B, Albores J, Wang T, Neville TH. A plasmapheresis protocol for refractory pulmonary alveolar proteinosis. Lung 2015; 193:209.</a></li><li><a class="nounderline abstract_t">Parker LA, Novotny DB. Recurrent alveolar proteinosis following double lung transplantation. Chest 1997; 111:1457.</a></li><li><a class="nounderline abstract_t">Miyazaki T, Tagawa T, Yamasaki N, et al. Two case reports of successful withdrawal of mycofenolate mofetil after living donor lobar lung transplantation. Transplant Proc 2013; 45:356.</a></li><li><a class="nounderline abstract_t">Tagawa T, Yamasaki N, Tsuchiya T, et al. Living-donor lobar lung transplantation for pulmonary alveolar proteinosis in an adult: report of a case. Surg Today 2011; 41:1142.</a></li><li><a class="nounderline abstract_t">Trukalj M, Perica M, Ferenčić Ž, et al. Successful Treatment of Autoimmune Pulmonary Alveolar Proteinosis in a Pediatric Patient. Am J Case Rep 2016; 17:641.</a></li><li><a class="nounderline abstract_t">Mucci A, Kunkiel J, Suzuki T, et al. Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency. Stem Cell Reports 2016; 7:292.</a></li><li><a class="nounderline abstract_t">Lachmann N, Happle C, Ackermann M, et al. Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2014; 189:167.</a></li><li><a class="nounderline abstract_t">McCarthy C, Lee E, Bridges JP, et al. Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis. Nat Commun 2018; 9:3127.</a></li><li><a class="nounderline abstract_t">Shi S, Wang R, Chen L, et al. Long-term follow-up and successful treatment of pulmonary alveolar proteinosis without hypercholesterolemia with statin therapy: a case report. J Int Med Res 2021; 49:3000605211010046.</a></li><li><a class="nounderline abstract_t">Dirksen U, Nishinakamura R, Groneck P, et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 1997; 100:2211.</a></li><li><a class="nounderline abstract_t">Akasaka K, Tanaka T, Kitamura N, et al. Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study. BMC Pulm Med 2015; 15:88.</a></li><li><a class="nounderline abstract_t">Chaulagain CP, Pilichowska M, Brinckerhoff L, et al. Secondary pulmonary alveolar proteinosis in hematologic malignancies. Hematol Oncol Stem Cell Ther 2014; 7:127.</a></li><li><a class="nounderline abstract_t">Cordonnier C, Fleury-Feith J, Escudier E, et al. Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am J Respir Crit Care Med 1994; 149:788.</a></li><li><a class="nounderline abstract_t">Ishii H, Seymour JF, Tazawa R, et al. Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. BMC Pulm Med 2014; 14:37.</a></li><li><a class="nounderline abstract_t">Hisata S, Moriyama H, Tazawa R, et al. Development of pulmonary alveolar proteinosis following exposure to dust after the Great East Japan Earthquake. Respir Investig 2013; 51:212.</a></li><li><a class="nounderline abstract_t">Cummings KJ, Donat WE, Ettensohn DB, et al. Pulmonary alveolar proteinosis in workers at an indium processing facility. Am J Respir Crit Care Med 2010; 181:458.</a></li><li><a class="nounderline abstract_t">Chew R, Nigam S, Sivakumaran P. Alveolar proteinosis associated with aluminium dust inhalation. Occup Med (Lond) 2016; 66:492.</a></li><li><a class="nounderline abstract_t">Gaine SP, O'Marcaigh AS. Pulmonary alveolar proteinosis: lung transplant or bone marrow transplant? Chest 1998; 113:563.</a></li><li><a class="nounderline abstract_t">Takaki M, Tanaka T, Komohara Y, et al. Recurrence of pulmonary alveolar proteinosis after bilateral lung transplantation in a patient with a nonsense mutation in CSF2RB. Respir Med Case Rep 2016; 19:89.</a></li><li><a class="nounderline abstract_t">Uchida K, Beck DC, Yamamoto T, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007; 356:567.</a></li><li><a class="nounderline abstract_t">Witty LA, Tapson VF, Piantadosi CA. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore) 1994; 73:103.</a></li><li><a class="nounderline abstract_t">Punatar AD, Kusne S, Blair JE, et al. Opportunistic infections in patients with pulmonary alveolar proteinosis. J Infect 2012; 65:173.</a></li><li><a class="nounderline abstract_t">Rosen LB, Rocha Pereira N, Figueiredo C, et al. Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis. Clin Infect Dis 2015; 60:1017.</a></li><li><a class="nounderline abstract_t">Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med 2013; 34:110.</a></li><li><a class="nounderline abstract_t">Wu XK, Lin Q. Pulmonary alveolar proteinosis complicated with nocardiosis: A case report and review of the literature. World J Clin Cases 2021; 9:2874.</a></li><li><a class="nounderline abstract_t">Kho SS, Ganapaty S, Omar N, et al. Opportunistic actinomycosis in pulmonary alveolar proteinosis. Thorax 2022; 77:842.</a></li><li><a class="nounderline abstract_t">Mabo A, Borie R, Wemeau-Stervinou L, et al. Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort. Thorax 2023; 79:68.</a></li><li><a class="nounderline abstract_t">Goldstein LS, Kavuru MS, Curtis-McCarthy P, et al. Pulmonary alveolar proteinosis: clinical features and outcomes. Chest 1998; 114:1357.</a></li><li><a class="nounderline abstract_t">Akira M, Inoue Y, Arai T, et al. Pulmonary Fibrosis on High-Resolution CT of Patients With Pulmonary Alveolar Proteinosis. AJR Am J Roentgenol 2016; 207:544.</a></li></ol></div><div id="topicVersionRevision">Topic 4356 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10607805" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6492867" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pulmonary alveolar proteinosis: prospective clinical experience in 23 patients for 15 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1741546" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bronchoalveolar lavage cell data in alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29397349" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202348" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28301535" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Quantitative assessment of Pulmonary Alveolar Proteinosis (PAP) with ultra-dose CT and correlation with Pulmonary Function Tests (PFTs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12498816" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19407056" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Plasmapheresis for treatment of pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31483963" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Inhaled GM-CSF for Pulmonary Alveolar Proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16517574" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27514590" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pulmonary Alveolar Proteinosis Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26481735" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Whole Lung Lavage Treatment of Chinese Patients with Autoimmune Pulmonary Alveolar Proteinosis: A Retrospective Long-term Follow-up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23036113" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Autoimmune pulmonary alveolar proteinosis: treatment options in year 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28421817" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sequential Granulocyte-Macrophage Colony-Stimulating Factor Inhalation after Whole-Lung Lavage for Pulmonary Alveolar Proteinosis. A Report of Five Intractable Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6368143" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14259213" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : PULMONARY ALVEOLAR PROTEINOSIS. REPORT OF SIX CASES, REVIEW OF THE LITERATURE, AND FORMULATION OF A NEW THEORY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15083749" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21900000" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21632797" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19995769" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Whole-lung lavage for pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28118623" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy of Whole-Lung Lavage in Pulmonary Alveolar Proteinosis: A Multicenter International Study of GELF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34277049" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy of whole lung lavage in pulmonary alveolar proteinosis: a 20-year experience at a reference center in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27577926" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26795910" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Anesthetic Management for Whole Lung Lavage in Patients with Pulmonary Alveolar Proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8486019" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A comparison of manual to mechanical chest percussion for clearance of alveolar material in patients with pulmonary alveolar proteinosis (phospholipidosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22496317" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34151899" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Increased Efficacy of Whole Lung Lavage Treatment in Alveolar Proteinosis Using a New Modified Lavage Technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865710" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Milky fluid from the lungs: pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26495308" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Respiratory strategies and airway management in patients with pulmonary alveolar proteinosis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29652291" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Whole-lung lavage in a patient with pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12119235" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary alveolar proteinosis: progress in the first 44 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764303" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840407" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15618581" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167854" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8965913" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11462071" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12200534" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : GM-CSF therapy in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612307" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27783330" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37973175" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22016491" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effectiveness of granulocyte-macrophage colony-stimulating factor therapy in autoimmune pulmonary alveolar proteinosis: a meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15735059" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507860" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265094" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Quantitative analysis of longitudinal response to aerosolized granulocyte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22112784" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37993127" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Nebulised granulocyte-macrophage colony-stimulating factor (GM-CSF) in autoimmune pulmonary alveolar proteinosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32897035" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9763547" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24890235" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32615994" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22379153" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19483052" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Rituximab therapy in autoimmune pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855439" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Therapeutic effectiveness of rituximab in a patient with unresponsive autoimmune pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21478218" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22697800" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29695229" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Rituximab for auto-immune alveolar proteinosis, a real life cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663343" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Plasmapheresis, GM-CSF, and alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557091" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A plasmapheresis protocol for refractory pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149615" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Recurrent alveolar proteinosis following double lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375323" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Two case reports of successful withdrawal of mycofenolate mofetil after living donor lobar lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21773908" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Living-donor lobar lung transplantation for pulmonary alveolar proteinosis in an adult: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27592713" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Successful Treatment of Autoimmune Pulmonary Alveolar Proteinosis in a Pediatric Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27453007" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24279725" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30087322" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33926277" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-term follow-up and successful treatment of pulmonary alveolar proteinosis without hypercholesterolemia with statin therapy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9410898" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26264717" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25300566" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Secondary pulmonary alveolar proteinosis in hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8118651" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24597668" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24238228" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Development of pulmonary alveolar proteinosis following exposure to dust after the Great East Japan Earthquake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20019344" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pulmonary alveolar proteinosis in workers at an indium processing facility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27099254" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Alveolar proteinosis associated with aluminium dust inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498994" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pulmonary alveolar proteinosis: lung transplant or bone marrow transplant?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27595063" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Recurrence of pulmonary alveolar proteinosis after bilateral lung transplantation in a patient with a nonsense mutation in CSF2RB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287477" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8152364" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Isolation of mycobacteria in patients with pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22484272" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Opportunistic infections in patients with pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25472947" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460011" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Underlying host risk factors for nontuberculous mycobacterial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33969072" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pulmonary alveolar proteinosis complicated with nocardiosis: A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35304426" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Opportunistic actinomycosis in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37758458" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9824014" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pulmonary alveolar proteinosis: clinical features and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27548000" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pulmonary Fibrosis on High-Resolution CT of Patients With Pulmonary Alveolar Proteinosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
